Kingchem (Liaoning) Life Science Co., Ltd. (SHE:301509)
China · Delayed Price · Currency is CNY 30.31
-0.05 (-0.16%)
At close: Oct 9, 2026
SHE:301509 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 598.33 | 637.42 | 496.79 | 766.71 | 716.22 | 547.15 |
Other Revenue | 1.96 | 1.95 | 0.23 | 0.12 | 0.45 | 2.05 |
| 600.3 | 639.37 | 497.01 | 766.82 | 716.67 | 549.19 | |
Revenue Growth | 2.89% | 28.64% | -35.19% | 7.00% | 30.50% | 18.25% |
Cost of Revenue | 378.26 | 384.38 | 341.97 | 421.48 | 413.02 | 337.99 |
Gross Profit | 222.04 | 255 | 155.04 | 345.35 | 303.65 | 211.2 |
Selling, General & Admin | 114.51 | 116.19 | 107.68 | 115.12 | 107.52 | 88.58 |
Research & Development | 38.15 | 35.91 | 35.53 | 30.04 | 25.99 | 24.63 |
Other Operating Expenses | 10.87 | 8.15 | 6.17 | 6.12 | 5.37 | 4.06 |
Operating Expenses | 163.77 | 162.36 | 147.44 | 154.35 | 136.26 | 118.75 |
Operating Income | 58.27 | 92.64 | 7.59 | 191 | 167.39 | 92.45 |
Interest Expense | -0.18 | -0.19 | -0.32 | -2.2 | -2.71 | -2.48 |
Interest & Investment Income | 26.73 | 30.17 | 25.19 | 8.64 | 0.74 | 0.55 |
Currency Exchange Gain (Loss) | -19.29 | -7.12 | 4.1 | 1.8 | 21.56 | -2.74 |
Other Non Operating Income (Expenses) | -0.23 | -0.28 | 0.55 | 2.15 | -2.39 | 0.38 |
EBT Excluding Unusual Items | 65.3 | 115.21 | 37.11 | 201.38 | 184.6 | 88.15 |
Gain (Loss) on Sale of Investments | 3.68 | 3.49 | 0.46 | - | -0.36 | -0.04 |
Gain (Loss) on Sale of Assets | -0.01 | - | -0.59 | -0.49 | - | 0.03 |
Asset Writedown | -1.82 | -1.82 | -4.07 | -0.36 | -0.05 | -0.66 |
Other Unusual Items | 5.41 | 4.04 | 6.24 | 2.88 | 9.59 | 12.36 |
Pretax Income | 72.56 | 120.92 | 39.26 | 203.41 | 193.77 | 99.84 |
Income Tax Expense | 9.24 | 16.11 | 0.66 | 29.83 | 32.32 | 15.29 |
Net Income | 63.32 | 104.81 | 38.61 | 173.57 | 161.45 | 84.55 |
Net Income to Common | 63.32 | 104.81 | 38.61 | 173.57 | 161.45 | 84.55 |
Net Income Growth | -19.11% | 171.46% | -77.76% | 7.51% | 90.96% | 43.46% |
Shares Outstanding (Basic) | 121 | 120 | 121 | 100 | 90 | 90 |
Shares Outstanding (Diluted) | 121 | 120 | 121 | 100 | 90 | 90 |
Shares Change | 0.15% | -0.15% | 20.26% | 10.97% | 0.77% | 28.18% |
EPS (Basic) | 0.52 | 0.87 | 0.32 | 1.73 | 1.79 | 0.94 |
EPS (Diluted) | 0.52 | 0.87 | 0.32 | 1.73 | 1.79 | 0.94 |
EPS Growth | -19.23% | 171.88% | -81.50% | -3.12% | 89.50% | 11.92% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 77.45 | 128.36 | 100.8 | 82.26 | 114.86 | -98.39 |
Free Cash Flow Per Share | 0.64 | 1.06 | 0.83 | 0.82 | 1.27 | -1.10 |
Dividend Per Share | 0.900 | 0.900 | 0.400 | 0.571 | - | - |
Dividend Growth | 125.00% | 125.00% | -30.00% | - | - | - |
Gross Margin | 36.99% | 39.88% | 31.19% | 45.04% | 42.37% | 38.46% |
Operating Margin | 9.71% | 14.49% | 1.53% | 24.91% | 23.36% | 16.83% |
Profit Margin | 10.55% | 16.39% | 7.77% | 22.63% | 22.53% | 15.39% |
Free Cash Flow Margin | 12.90% | 20.08% | 20.28% | 10.73% | 16.03% | -17.91% |
EBITDA | 117.25 | 152.68 | 73.04 | 256.84 | 219.14 | 135.15 |
EBITDA Margin | 19.53% | 23.88% | 14.70% | 33.49% | 30.58% | 24.61% |
D&A For EBITDA | 58.98 | 60.04 | 65.44 | 65.85 | 51.75 | 42.7 |
EBIT | 58.27 | 92.64 | 7.59 | 191 | 167.39 | 92.45 |
EBIT Margin | 9.71% | 14.49% | 1.53% | 24.91% | 23.36% | 16.83% |
Effective Tax Rate | 12.74% | 13.33% | 1.67% | 14.67% | 16.68% | 15.32% |
Revenue as Reported | 600.3 | 639.37 | 497.01 | 766.82 | 716.67 | - |
Advertising Expenses | - | 2.74 | 2.37 | 2.38 | 1.81 | 0.81 |